Zimbabwe has become the first country in Africa and the third in the world to approve a long-acting HIV prevention drug recommended by the World Health Organization. Zimbabwe, which has seen AIDS-related deaths fall from 130,000 in 2002 to 20,000 in 2021 and aims to end AIDS by 2030, has already reached a target known as 90-90-90. That means 90% of people living with HIV knowing their status; 90% getting antiretroviral treatment; and 90% having the virus suppressed. The WHO says the injectable drug, cabotegravir, is highly effective at reducing transmission among people at most risk of contracting HIV. Nyasha Sithole, of Development Agenda for Girls and Women in Africa, said it “will contribute to our basket of HIV prevention tools that work for us as girls and women in Zimbabwe.”

Read Full Story